Noncovalent assembly of targeted carbon nanovectors enables synergistic drug and radiation cancer therapy in vivo

ACS Nano

Volumn 6, Issue 3, 2012, Pages 2497-2505

  Sano, Daisuke ^a,d,e   Berlin, Jacob M ^c,d,e   Pham, Tam T ^c   Marcano, Daniela C ^c   Valdecanas, David R ^b   Zhou, Ge ^a   Milas, Luka ^b   Myers, Jeffrey N ^a   Tour, James M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RICE UNIVERSITY   (United States)

^d YOKOHAMA CITY UNIVERSITY   (Japan)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

cancer; cetuximab; EGFR; hydrophilic carbon clusters; nanovectors; targeted drug delivery

Indexed keywords

CANCER; CETUXIMAB; EGFR; HYDROPHILIC CARBONS; NANOVECTORS; TARGETED DRUG DELIVERY;

CARBON CLUSTERS; DRUG DELIVERY; DRUG INTERACTIONS; POLYETHYLENE GLYCOLS; TUMORS;

RADIOTHERAPY;

CARBON; CETUXIMAB; DRUG CARRIER; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; NANOMATERIAL; PACLITAXEL;

ANIMAL; ARTICLE; CHEMISTRY; DRUG EFFECT; HEAD AND NECK TUMOR; HUMAN; MALE; MOUSE; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; CARBON; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG CARRIERS; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; NANOSTRUCTURES; PACLITAXEL; POLYETHYLENE GLYCOLS; TUMOR BURDEN;

EID: 84859132867     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn204885f     Document Type: Article

References (31)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer Statistics, 2010 CA Cancer J. Clin. 2010, 60, 277-300
2. Carvalho, A. L.; Nishimoto, I. N.; Califano, J. A.; Kowalski, L. P. Trends in Incidence and Prognosis for Head and Neck Cancer in the United States: a Site-Specific Analysis of the SEER Database Int. J. Cancer 2005, 114, 806-816
3. Lango, M. N. Multimodal Treatment for Head and Neck Cancer Surg. Clin. North Am. 2009, 89, 43-52, viii
4. Hamburg, M. A.; Collins, F. S. The Path to Personalized Medicine New Engl. J. Med. 2010, 363, 301-304
5. Schilsky, R. L. Personalized Medicine in Oncology: the Future is Now Nat. Rev. Drug Discovery 2010, 9, 363-366
6. Riehemann, K.; Schneider, S. W.; Luger, T. A.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-Challenge and Perspectives Angew. Chem., Int. Ed. 2009, 48, 872-897
7. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges Nat. Rev. Cancer 2005, 5, 161-171
8. Service, R. F. Materials and Biology. Nanotechnology Takes Aim at Cancer Science 2005, 310, 1132-1134
9. Sinha, R.; Kim, G. J.; Nie, S.; Shin, D. M. Nanotechnology in Cancer Therapeutics: Bioconjugated Nanoparticles for Drug Delivery Mol. Cancer Ther. 2006, 5, 1909-1917
10. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C.; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy Nat. Nanotechnol. 2007, 2, 751-760
11. Davis, M. E.; Chen, Z. G.; Shin, D. M. Nanoparticle Therapeutics: an Emerging Treatment Modality for Cancer Nat. Rev. Drug Discovery 2008, 7, 771-782
12. Bonner, J. A.; Maihle, N. J.; Folven, B. R.; Christianson, T. J. H.; Spain, K. The Interaction of Epidermal Growth-Factor and Radiation in Human Head and Neck Squamous-Cell Carcinoma Cell-Lines with Vastly Different Radiosensitivities Int. J. Radiat. Oncol. 1994, 29, 243-247
13. Huang, S. M.; Bock, J. M.; Harari, P. M. Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck Cancer Res. 1999, 59, 1935-1940
14. Saleh, M. N.; Raisch, K. P.; Stackhouse, M. A.; Grizzle, W. E.; Bonner, J. A.; Mayo, M. S.; Kim, H. G.; Meredith, R. F.; Wheeler, R. H.; Buchsbaum, D. J. Combined Modality Therapy of A431 Human Epidermoid Cancer Using Anti-EGFr Antibody C225 and Radiation Cancer Biother. Radiopharm. 1999, 14, 451-463
15. Vermorken, J. B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H. R.; Cupissol, D. et al. Platinum-Based Chemotherapy Plus Cetuximab in Head and Neck Cancer New Engl. J. Med. 2008, 359, 1116-1127
16. Bonner, J. A.; Harari, P. M.; Giralt, J.; Azarnia, N.; Shin, D. M.; Cohen, R. B.; Jones, C. U.; Sur, R.; Raben, D.; Jassem, J. et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck New Engl. J. Med. 2006, 354, 567-578
17. Rubin Grandis, J.; Melhem, M. F.; Gooding, W. E.; Day, R.; Holst, V. A.; Wagener, M. M.; Drenning, S. D.; Tweardy, D. J. Levels of TGF- Alpha and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival J. Natl. Cancer Inst. 1998, 90, 824-832
18. Berlin, J. M.; Leonard, A. D.; Pham, T. T.; Sano, D.; Marcano, D. C.; Yan, S.; Fiorentino, S.; Milas, Z. L.; Kosynkin, D. V.; Price, B. K. et al. Effective Drug Delivery, In Vitro and In Vivo, by Carbon-Based Nanovectors Noncovalently Loaded with Unmodified Paclitaxel ACS Nano 2010, 4, 4621-4636
19. Chen, Z. Y.; Kobashi, K.; Rauwald, U.; Booker, R.; Fan, H.; Hwang, W. F.; Tour, J. M. Soluble Ultra-Short Single-Walled Carbon Nanotubes J. Am. Chem. Soc. 2006, 128, 10568-10571
20. Price, B. K.; Lomeda, J. R.; Tour, J. M. Aggressively Oxidized Ultra-Short Single-Walled Carbon Nanotubes Having Oxidized Sidewalls Chem. Mater. 2009, 21, 3917-3923
21. Stephenson, J. J.; Hudson, J. L.; Leonard, A. D.; Price, B. K.; Tour, J. M. Repetitive Functionalization of Water-Soluble Single-Walled Carbon Nanotubes. Addition of Acid-Sensitive Addends Chem. Mater. 2007, 19, 3491-3498
22. Berlin, J. M.; Pham, T. T.; Sano, D.; Mohamedali, K. A.; Marcano, D. C.; Myers, J. N.; Tour, J. M. Noncovalent Functionalization of Carbon Nanovectors with an Antibody Enables Targeted Drug Delivery ACS Nano 2011, 5, 6643-6650
23. Gupta, A. K.; McKenna, W. G.; Weber, C. N.; Feldman, M. D.; Goldsmith, J. D.; Mick, R.; Machtay, M.; Rosenthal, D. I.; Bakanauskas, V. J.; Cerniglia, G. J. et al. Local Recurrence in Head and Neck Cancer: Relationship to Radiation Resistance and Signal Transduction Clin. Cancer Res. 2002, 8, 885-892
24. Milas, L.; Mason, K.; Hunter, N.; Petersen, S.; Yamakawa, M.; Ang, K.; Mendelsohn, J.; Fan, Z. In Vivo Enhancement of Tumor Radioresponse by C225 Antiepidermal Growth Factor Receptor Antibody Clin. Cancer Res. 2000, 6, 701-708
25. Sano, D.; Matsumoto, F.; Valdecanas, D.; Zhao, M.; Molkentine, D. P.; Takahashi, Y.; Hanna, E. Y.; Papadimitrakopoulou, V. A.; Heymach, J. V.; Milas, L. et al. Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells Sensitivity to Cisplatin and Radiation in Vivo and in Vitro Clin. Cancer Res. 2011, 17 (7) 1815-1827
26. Milas, L.; Fujii, T.; Hunter, N.; Elshaikh, M.; Mason, K.; Plunkett, W.; Ang, K. K.; Hittelman, W. Enhancement of Tumor Radioresponse in Vivo by Gemcitabine Cancer Res. 1999, 59, 107-114
27. Sawai, A.; Chandarlapaty, S.; Greulich, H.; Gonen, M.; Ye, Q.; Arteaga, C. L.; Sellers, W.; Rosen, N.; Solit, D. B. Inhibition of Hsp90 Down-Regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel Cancer Res. 2008, 68, 589-596
28. Zhou, G.; Xie, T. X.; Zhao, M.; Jasser, S. A.; Younes, M. N.; Sano, D.; Lin, J.; Kupferman, M. E.; Santillan, A. A.; Patel, V. et al. Reciprocal Negative Regulation Between S100A7/Psoriasin and Beta -Catenin Signaling Plays an Important Role in Tumor Progression of Squamous Cell Carcinoma of Oral Cavity Oncogene 2008, 27, 3527-3538
29. Sano, D.; Choi, S.; Milas, Z. L.; Zhou, G.; Galer, C. E.; Su, Y. W.; Gule, M.; Zhao, M.; Zhu, Z.; Myers, J. N. The Effect of Combination Anti-Endothelial Growth Factor Receptor and Anti-Vascular Endothelial Growth Factor Receptor 2 Targeted Therapy on Lymph Node Metastasis: a Study in an Orthotopic Nude Mouse Model of Squamous Cell Carcinoma of the Oral Tongue Arch. Otolaryngol. Head Neck Surg. 2009, 135, 411-420
30. Myers, J. N.; Holsinger, F. C.; Jasser, S. A.; Bekele, B. N.; Fidler, I. J. An Orthotopic Nude Mouse Model of Oral Tongue Squamous Cell Carcinoma Clin. Cancer Res. 2002, 8, 293-298
31. Choi, H. S.; Liu, W.; Liu, F.; Nasr, K.; Misra, P.; Bawendi, M. G.; Frangioni, J. V. Design Considerations for Tumour-Targeted Nanoparticles Nat. Nanotechnol. 2010, 5, 42-47